Improvement in ppFEV1 correlates with reduction in DNA content and viscoelasticity of CF patients sputa following treatment with alidornase alfa
Improvement in ppFEV1 correlates with reduction in DNA content and viscoelasticity of CF patients sputa following treatment with alidornase alfa
Format
JPEG
Source
Protalix BioTherapeutics, Inc.